knowledge -WSS

knowledge

author：focus 2025-10-01 05:39:41 - browse：45621

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Medicare Advantage's lean provider networks lead CMS complaints

focus

WSS

Vir antibody drug aimed at influenza A fails in clinical trial

Stanford president faces new allegations over 1999 paper

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Ending racial health disparities hinges on penalties, political will

Eli Lilly’s Zepbound improved liver scarring in mid

7 more heat

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Medical leaders decry Supreme Court decision on affirmative action

UnitedHealth CEO's Medicaid comments send insurer stocks diving

BioMarin wins approval for gene therapy to treat hemophilia A

Stopping antidepressants leads to symptoms for 1 in 6 patients

At least 13 dead in Texas as scorching temps continue

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Apple is now the first public company to be valued at $3 trillion

Why Congress must ban federal programs from using QALYs

Duchenne breakthrough therapy leaves behind pioneering families

Congress needs to close a vaccine

knowledge

Eli Lilly’s Zepbound improved liver scarring in mid

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

A new initiative will help leaders fight the next pandemic

Winning ticket for $1 billion Powerball jackpot sold in California

Medicare Advantage's lean provider networks lead CMS complaints

Stanford president faces new allegations over 1999 paper

knowledge

focus

explore

explore